Clinical trial NCT03381482: Ectosomes, New Biomarkers of Tau Pathology?
Official title: Ectosomes, New Biomarkers of Tau Pathology?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Alzheimer Disease
Keywords: Alzheimer disease
Extracellular vesicles
Biomarker
Tau
CSF
Plasma
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2017-12-22
Enrollment: 100
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Subjects intended to participate in group 1 have to undergo a lumbar puncture for other reasons than a cognitive complaint. They will be identified in the anaesthesiology department among patients who are waiting for scheduled orthopaedic surgery needing spinal anaesthesia. They will have the sample collection done with its specific procedures in the same time.

if a subject is already followed at the MRRC and meets group 1 eligibility criteria, he/she could be asked to participate in the study and thus be enrolled and followed by a MRRC investigator.

Patients intended to participate in groups 2 to 5 will be identified at the MRRC during their scheduled visit with the investigators specialized in neurology/geriatric medicine.

Brief summary: In Alzheimer's disease (AD), neurofibrillary degeneration (NFD) is characterized by the intraneuronal aggregation of Tau proteins. The pathology progresses through a hierarchical pathway that may be associated with the intercellular transmission of pathology as demonstrated in our rat models. This transmission implies that Tau is actively secreted and may participate to the first steps of Tau pathology spreading. It is demonstrated in cell lines and animal models (rodents and non-human primates) that Tau is secreted not only in free forms but also in extracellular vesicles. If Tau is found in biological fluids before neuronal death it may represent an early marker of the NFD and will also define therapeutically targets. In this context, the aim is now to transfer this knowledge in humans and to decipher the nature of Tau secreted in plasma and cerebrospinal fluids collected from healthy controls to AD patients, and to decipher if the presence of tau inside vesicles is influenced by the pathology.


Eligibility criteria: Inclusion Criteria:

* Subjects able to undergo a lumbar puncture;
* Subjects who have a partner who will be required for driving back the subject after the lumbar punction for safety reasons (not required for control subjects);
* Subjects (or the study partner for group 5) capable of and willing to comply with the protocol and to give their written informed consents after having received and understood the subject information. According to the legal protection or the mental capacities of the subject, he/she will be accompanied by him/her legally acceptable representative during this procedure;
* Blood coagulation testing
* Subjects registered with the French Social Security, in agreement with the French law on biomedical experimentation.

Group 1: controls

* absence of cognitive complaint
* absence of significant cognitive impairment: MMSE\>27
* Negative ApoE4 status (ε 4-/ ε 4-) No family history of AD at first degree Group 2: asymptomatic cases with high risk to develop AD
* absence of cognitive complaint
* absence of significant cognitive impairment : MMSE\>27
* known ApoE4 status or family history of AD at first degree Group 3: cases with isolated cognitive complaint
* presence of a cognitive complaint
* absence of cognitive impairment assessed by MMSE\>27 and standard neuropsychological examination (performed \< 1 year) Group 4: prodromal AD according to the 2007 criteria (Dubois et al., 2007)
* progressive and significant episodic memory impairment \>6 months
* And at least one of the following: medial temporal atrophy of brain MRI / low Ab42 and increased total and phosphorylated Tau protein in the CSF/ bilateral temporoparietal hypometabolism on brain FDG-PET/ positive amyloid brain PET if available
* exclusion of any differential diagnoses Group 5: Mild to moderate probable AD-type dementia according to the NIA 2011 criteria
* progressive and significant cognitive decline \>6 months
* amnestic or any other predominant clinical presentation
* exclusion of any differential diagnoses
* MMSE between 15 and 26 (inclusive)

Exclusion Criteria:

* Subjects with dementia caused by a non-neurodegenerative disease, including patients with severe cerebrovascular risk factor load;

Associated Illnesses or conditions:

* Subjects with other neurodegenerative disease such as fronto-temporal dementia (FTD), Lewy body dementia and Parkinson's disease;
* Subjects with other serious neurological disorder such as brain tumour, stroke, epilepsy, hydrocephalus and any condition which contraindicates, in the investigator's judgment, entry to the study;
* Subjects with demyelinating diseases of the peripheral nervous system such as Guillain-Barre Syndrome;

Biological exclusion criteria:

* Subjects with known active Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) or Human Immunodeficiency Virus (HIV);
* Subjects with clinical or significant laboratory abnormalities, in the judgment of the investigator;

Others:

* Subjects with excessive alcohol intake or drug abuse, in the judgment of the investigator;
* Subjects who have contraindications to perform a lumbar puncture;
* Subjects who, in the opinion of the Investigator, have a risk of non-compliance to the study procedures or who are otherwise not appropriate to include in this clinical trial (for example, being impossible to contact in case of emergency).

Primary outcomes:
measure: Presence of Tau in extracellular vesicles in CSF
timeFrame: Baseline
Secondary outcomes:
measure: The ratio of free Tau/vesicular Tau for all groups will be assessed with samples obtained during the visit.
timeFrame: Baseline
measure: The presence of clusters of the epigenetic markers H3K9me3 in nuclei of peripheral blood mononuclear cells for all groups will be assessed with samples obtained during the visit.
timeFrame: Baseline
Other outcomes:
Locations:
city: Lille
country: France
facility: Hôpital Roger Salengro, CHRU
Study officials:
affiliation: University Hospital, Lille
name: Vincent DERAMECOURT, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References: